Nuvalent, Inc. - Class A

The momentum for this stock is not very good. Nuvalent, Inc. - Class A is not very popular among insiders. Nuvalent, Inc. - Class A is a mediocre stock to choose.

News

Nuvalent (NASDAQ:NUVL) Stock Rating Reaffirmed by Wedbush

Ticker Report Nuvalent (NASDAQ:NUVL - Get Free Report)s stock had its "outperform" rating reaffirmed by research analysts at Wedbush in a research report issued on Monday, MarketBeat reports. They currently...\n more…

Nuvalent announces updated data from ALKOVE-1 trial at ESMO

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles

PR Newswire Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles Updated Data for Nuvalent's...\n more…

Darlene Noci Sells 5,000 Shares of Nuvalent, Inc. (NASDAQ:NUVL) Stock

Ticker Report Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) insider Darlene Noci sold 5,000 shares of the firm's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $84.43...\n more…

Nuvalent, Inc. (NASDAQ:NUVL) CFO Alexandra Balcom Sells 10,000 Shares

Zolmax Nuvalent, Inc. (NASDAQ:NUVL - Get Free Report) CFO Alexandra Balcom sold 10,000 shares of the company's stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average...\n more…

Nuvalent (NASDAQ:NUVL) Price Target Raised to $100.00 at JPMorgan Chase & Co.

Zolmax Nuvalent (NASDAQ:NUVL - Get Free Report) had its price objective increased by research analysts at JPMorgan Chase Co. from $90.00 to $100.00 in a research report issued on Wednesday, Benzinga...\n more…